摘要
目的探讨两性霉素B雾化吸入联合伏立康唑静滴治疗恶性血液病患者下呼吸道真菌感染的临床疗效及安全性。方法将62例恶性血液病合并下呼吸道真菌感染的患者随机分为观察组和对照组,各31例。观察组选用25mg两性霉素B溶于20ml0.9%氯化钠注射液中,每次取10～12.5mg雾化吸入,氧流量8～10L/min,持续15～20min,2次/d,疗程30d,同时给予伏立康唑针首剂0.4g溶于0.9%氯化钠注射液中250ml中静滴,续以0.2g溶于0.9%氯化钠注射液250ml中静滴,1次/12h,疗程30d。对照组予伏立康唑针首剂0.4g溶于0.9%氯化钠注射液250ml中静滴,续以0.2g溶于0.9%氯化钠注射液250ml中静滴,1次/12h,疗程30d。结果观察组、对照组有效率分别为87.0%、54.8%,两组有效率比较差异有统计学意义(P<0.05);观察组、对照组不良反应发生率分别为6.45%和6.45%,两组比较差异无统计学意义(P>0.05)。结论两性霉素B雾化吸入联合伏立康唑静滴治疗下呼吸道真菌感染安全有效,不良反应少,值得临床推广。
Objective To evaluate the efficacy and safety of aerosol inhalation of amphotericin B adjoin voriconazole for primary therapy of invasive fungal infection（IFI）in hematologic patients.Methods 62 hematologic patients with lower respiratory tract fungal infections were randomly divided into therapy group and control group;group.Results The clinical effective rate in trial group and control group were 87.0% and 54.8%（P0.05）,adverse reaction rates were 6.45% and 6.45%（P0.05） respectively.Conclusion Aerosol inhalation of amphotericin B adjoin voriconazole is effective and safe in lower respiratory tract fungal infections.
出处
《中外医学研究》
2011年第9期14-15,共2页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
两性霉素B
雾化吸入
下呼吸道真菌感染
Amphotericin B
Aerosol inhalation treatment
Lower respiratory tract fungal infection
